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Purpose: The aim of this study was to evaluate the effect of
lowering the fasting plasma glucose (FPG) criteria for impaired
fasting glucose (IFG) on the prevalence of IFG and the risk for
the development of diabetes associated with IFG in Koreans.
Materials and Methods: A total of 7,211 subjects who had
normal glucose tolerance (NGT) or IFG were recruited. Subjects
were evaluated at baseline and after two years follow up.
Clinical data including total cholesterol, FPG and blood pressure
were examined. Results: Lowering the criteria for IFG from 6.1
mmol/L (110 mg/dL) to 5.6 mmol/L (100mg/dL) increased the
prevalence of IFG from 6.6% (494 subjects) to 24.4% (1829
subjects). After the 2 years follow up period, 91 subjects (1.3%)
developed diabetes. Twenty one (0.3%) subjects developed
diabetes among 5,382 NGT subjects and 70 (3.8%) subjects
developed diabetes among 1,829 IFG (5.6-7.0mmol/L) subjects.
Lowering the IFG threshold from 6.1 mmol/L to 5.6 mmol/L
resulted in a 18.4% decrease in specificity and 23.9% increase
in sensitivity for predicting diabetes. The baseline FPG for pre-
dicting the development of diabetes after 2 years at a point on
the receiver operating characteristic curve that was closest to the
ideal 100% sensitivity and 100% specificity was 5.7 mmol/L
(103 mg/dL). Conclusion: Lowering the FPG criterion of IFG
should have benefits in predicting new onset type 2 diabetes mel-
litus in Koreans. The economic and health benefits of applying
the new IFG criteria should be evaluated in future studies.
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INTRODUCTION
In 1997, the American Diabetes Association
(ADA) first introduced a category of impaired
fasting glucose (IFG) that included a fasting
plasma glucose (FPG) level between 6.1 and < 7.0
mmol/L ( 110 and < 126 mg/dL).
1 The World
Health Organization adopted this new criterion in
1999.
2 The main reason for the new criteria was
to create a fasting category that would be analog-
ous to impaired glucose tolerance (IGT) based on
the 75-g post-load glucose levels. In 2003, the
ADA recommended that the threshold for
diagnosing IFG should be lowered to 5.6 mmol/L
or 100 mg/dL.
3 This was justified by the desire to
identify similar proportions of the population
with IFG and IGT and to produce an equivalent
predictive power for progression to diabetes from
the IGT and IFG categories. Data from the Pima
Indians showed that the risk of diabetes increased
markedly at an FPG concentration of higher than
5.6 mmol/L.
4 However, there has been debate
over the advantages and the cost-benefit of this
change.
5-7
The lowering of the criteria for IFG from 6.1
mmol/L to 5.6 mmol/L increased the prevalence
of IFG two to fivefold in most populations,
6-9
which could have a significant impact on the
individuals as well as the healthcare system. The
category of IFG is defined as the metabolic stage
that is intermediate between the upper limit of
normal FPG and the lower limit of diabetic FPG.
IFG is not a clinical disease entity but rather a risk
factor for the development of future diabetes.
10
Therefore, it is important to optimize the IFG
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criteria. In reality, optimization requires conside-
ration of the costs of predicting or not predicting
a diagnosis of diabetes when diabetes does or
does not ultimately develop. There also may be an
ethnic difference in the criteria for IFG. Unlike
type 2 diabetic patients in western countries, most
Korean type 2 diabetic patients are not obese and
insulin deficiency, rather than insulin resistance, is
suggested to be the major pathogenic mecha-
nism.
11,12 We evaluated the prevalence of IFG
according to the old and new IFG criteria and the
prevalence of normal glucose tolerance (NGT),
IFG or diabetes after 2 years according to the
baseline FPG level. We examined whether lowering




Among the subjects who underwent a medical
examination from January, 2002 to December,
2002 at Inha University Hospital, 7,510 subjects
underwent a follow up medical examination 2
years later in 2004. Twenty subjects were excluded
due to diagnosis of malignancy prior to the study
endpoint in 2004. A total of 279 subjects who were
diagnosed with diabetes before or during their
first examination in 2002 (223 subjects were newly
diagnosed at the examination in 2002 and 56
subjects were diagnosed with diabetes before the
health examination in 2002) were also excluded.
Finally, 7,211 subjects (6,224 men and 987 women)
who had either NGT or IFG were included in this
study. This study was approved by the Institu-
tional Review Board at Inha University Hospital.
Methods
The height, weight, blood pressure, FPG and
total cholesterol were measured at baseline and
after 2 years. The height and weight were
measured to the nearest 0.1 cm and 0.1 kg, while
the subjects were allowed to wear light clothing
and no shoes. Body mass index was calculated as
weight (kg) divided by the square of height (m).
Blood pressure was measured using an automatic
sphygmomanometer after the subject had been
seated for at least five minutes. Blood samples
were collected after overnight fasting. The fasting
glucose was measured by the glucose oxidase
method. Serum total cholesterol was measured
using an auto analyzer by the enzymatic colori-
metric method. The frequency of exercise was
determined for all subjects.
Diabetes was defined as a FPG value 7.0
mmol/L (126 mg/dL) or a prior diagnosis of
diabetes according to the ADA criteria.
3 IFG was
defined as a FPG value of 5.6 - 7.0 mmol/L (100 -
125 mg/dL) in the absence of a previous diagnosis
of diabetes according to the new ADA criteria.
3
Old IFG was defined as a FPG value of 6.1 - 7.0
mmol/L (110 - 125 mg/dL) in the absence of a
previous diagnosis of diabetes in accordance with
the old ADA criteria.
1 Newly included IFG was
defined as a FPG value of 5.6 - 6.0 mmol/L (100 -
109 mg/dL) in the absence of a previous diagnosis
of diabetes.
Statistical analysis
Statistical analyses were performed using SPSS
software (version 11.0; SPSS Inc, Chicago, IL,
USA) and MedCalc software (version 8.2, MedCalc
Software, Belgium). All continuous variables
were expressed as mean ± standard deviation.
Comparisons of clinical characteristics between
baseline and follow up were performed by the
paired t-test. Comparisons of clinical charac-
teristics at baseline between groups were
performed by independent sample t-test or the
chi-square test. Subjects were divided into 8
groups according to the baseline FPG. The
percentage of NGT subjects at follow up was
calculated as the total number of NGT subjects
divided by the number of subjects in each group
based on the baseline FPG concentration and
multiplied by 100. The percentage of subjects
with IFG and diabetes at the 2004 evaluation
were also calculated by similar methods. A
receiver operating characteristic (ROC) curve for
predicting the future onset of diabetes after 2
years follow up was derived by plotting the
sensitivity vs 1-specificity for the baseline FPG of
less than 126 mg/dL. The optimal cutoff point
was defined as the point on the ROC curveDiagnosis of Impaired Fasting Glucose
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closest to the point at a 1-specificity of 0 and a
sensitivity of 100%. A 2-sided value of p less than
0.05 was considered to be statistically significant.
RESULTS
Clinical characteristics of subjects
The mean age of the subjects was 38.8 ± 9.1
years. Clinical characteristics at baseline and after
the 2 years follow up period are shown in Table
1. Among 7,211 subjects, 5,382 subjects were NGT
and 1,829 subjects were IFG at baseline. Among
1,829 IFG subjects, 494 subjects were included in
the old IFG group and 1,335 subjects in the
newly included IFG group. Among the 5,382
NGT subjects, 4,483 (83.3%) subjects remained
NGT, 878 (16.3%) subjects developed IFG and 21
(0.4%) developed diabetes after 2 years. Among
1,829 IFG subjects, 908 (49.6%) subjects returned
to NGT, 851 (46.5%) remained to have IFG, and
70 (3.8%) developed diabetes after two years.
Among the newly included 1,335 IFG subjects,
747 (56%) subjects returned to NGT, 566 (42.4%)
remained IFG, and 22 (1.6%) developed diabetes.
Among the 494 old IFG subjects, 161 (32.6%)
returned to NGT, 285 (57.7%) remained IFG and
48 (9.7%) developed diabetes. Subjects who
developed diabetes during the 2 years period had
significantly older age, higher BMI, systolic and
diastolic blood pressure, fasting plasma glucose,
total cholesterol, alanine aminotransferase (ALT),
and gamma-glutamyl transpeptidase (gamma-GT)
levels (Table 2).
Table 1. Clinical Characteristics of Subjects (n = 7211) at Baseline and After 2 Years Follow-up
Baseline After 2 years p value
Weight (kg) 67.4 ± 10.4 67.9 ± 10.6 < 0.001
BMI (kg/m
2) 23.7 ± 2.9 23.9 ± 2.9 < 0.001
Glucose (mmol/L) 5.15 ± 0.61 5.22 ± 0.65 < 0.001
Total cholesterol (mmol/L) 4.88 ± 0.87 4.92 ± 0.86 < 0.001
Systolic BP (mmHg) 125.0 ± 14.8 129.4 ± 15.4 < 0.001
Diastolic BP (mmHg) 78.2 ± 11.1 77.5 ± 10.8 < 0.001
Frequency of exercise (/wk) 1.36 ± 1.68 1.59 ± 1.71 < 0.001
BMI, body mass index; BP, blood pressure.
Data are expressed as means ± SD.
Table 2. Baseline Characteristics of Non-Diabetic and New-Diabetic Subjects at 2 Years Follow-up
Non-diabetic Diabetic p value
n (M/F) 7120 (6139/981) 91 (85/6) 0.050
Age (yrs) 38.7 ± 9.1 43.4 ± 9.4 < 0.001
BMI (kg/m
2) 23.7 ± 2.9 25.6 ± 3.7 < 0.001
Systolic BP (mmHg) 124.9 ± 14.7 133.8 ± 19.3 < 0.001
Diastolic BP (mmHg) 78.2 ± 11.0 83.8 ± 13.6 < 0.001
Fasting glucose (mmol/L) 5.14 ± 0.60 6.01 ± 0.70 < 0.001
Total cholesterol (mmol/L) 4.88 ± 0.87 5.10 ± 1.00 0.020
ALT (IU/L) 32.3 ± 33.2 55.5 ± 37.2 < 0.001
gamma-GT (IU/L) 39.3 ± 38.3 73.6 ± 367.6 < 0.001
Frequency of exercise (/wk) 1.4 ± 1.7 1.4 ± 1.8 0.620
Family history of diabetes (%) 5.4 13.2 0.001
M, male; F, female; BMI, body mass index; BP, blood pressure.
Data are expressed as means ± SD.So Hun Kim, et al.
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Percentage of NGT, IFG, and newly developed
diabetes at follow up according to the fasting
glucose concentration at baseline
The percentage of NGT subjects at follow up
decreased with an increase in the FPG concen-
tration at baseline. The percentage of IFG subjects
and newly developed diabetic subjects at follow
up increased with the increase of FPG concentra-
tion at baseline (Fig. 1).
Comparison of the new and old diagnostic criteria
of IFG
Subjects in the old IFG group had significantly
older age, higher BMI, total cholesterol, and
systolic and diastolic blood pressure compared
with those in the newly included IFG group
(Table 3). In correctly predicting incident diabetes
in the 2 years follow-up period, the old criteria
had a sensitivity of 53%, specificity of 93.7%,
positive predictive value of 9.7%, and negative
predictive value of 99.4%. Applying the new
diagnostic criteria, the sensitivity was 76.9%,
specificity was 75.3%, positive predictive value
was 3.8%, and the negative predictive value was
99.6%. After applying the new IFG criteria the
specificity showed an 18.4% decrease whereas the
sensitivity showed a 23.9% increase compared to
the old IFG criteria. Using the ROC curve, the
cutoff point that maximizes the sum of the
sensitivity and specificity can be used to discrimi-
nate between the groups of subjects who have a
high risk of developing diabetes after 2 years. The
baseline FPG level at the point on the ROC curve
that was closest to the ideal of 100% sensitivity
and 100% specificity was 103 mg/dL (5.7 mmol/L).
The sensitivity and specificity of 103 mg/dL were
70.3% and 85.4%, respectively.
DISCUSSION
The IFG category was introduced to designate
Fig. 1. Percentage of normal glucose tolerance (A),
impaired fasting glucose (B), and diabetes mellitus (C)
in 2004 according to the fasting glucose concentration
in 2002.
A B
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the zone between the upper limit of normal FPG
and the lower limit of diabetic FPG. IFG repre-
sents an intermediate state of abnormal glucose
regulation and is a risk factor for future develop-
ment of diabetes. In 2003, the ADA recommended
that the lower limit for the diagnosis of IFG
should be changed from 6.1 to 5.6 mmol/L.
3 Type
2 diabetes is an epidemic, and the public health
burden of the disease remains enormous. The
magnitude of the epidemic, coupled with complex
treatment requirements that are difficult and
costly to implement, makes the prevention of
diabetes a critical public health goal.
13 People in
Asia develop diabetes at a lower degree of obesity
and at younger ages, suffer longer from chronic
diabetic complications, and die sooner than those
in developed countries.
14 Therefore, it is important
and necessary to evaluate the proper threshold for
the diagnosis of IFG in Koreans.
In this study, lowering the FPG criterion for IFG
from 6.1 to 5.6 mmol/L resulted in an increase of
prevalence of IFG from 6.9% to 25.3%. Lowering
the diagnostic threshold for IFG has increased the
prevalence of IFG two to fivefold in most popula-
tions,
6-9 which is consistent with the findings of
this study. Many people revert to normoglycaemia
on subsequent testing after a first test showing
raised glucose levels, and there is no fixed state
of pre-diabetes. In this study, 49.6% of patients
from the IFG group reverted to NGT on sub-
sequent testing, 56% from the newly included IFG
group and 32.6% from the old IFG group.
This study demonstrated that the incidence
rates of diabetes during 2 years for IFG categories
of 5.6 - 6.0 and 6.1 - 7.0 mmol/L were 1.6% and
9.7%, respectively. Lowering the FPG criteria for
IFG included more subjects who were younger,
had lower BMI, total cholesterol, and systolic and
diastolic blood pressure. The new diagnostic criteria
increased the sensitivity of predicting incident
diabetes after 2 years from 53% to 76.9% com-
pared to the old criteria. On the other hand, the
new criteria resulted in a decrease in specificity
from 93.7% to 76.9%. Using the ROC curve, the
cutoff point that maximizes the sum of sensitivity
and specificity was 5.7 mmol/L (103 mg/dL),
which is much lower than the cutoff value of the
old IFG criteria. The transition from impaired
fasting glucose to diabetes may take many years,
and current estimates indicate that most indivi-
duals with pre-diabetic states eventually develop
diabetes.
15-20 Therefore, considering the short follow
up period of 2 years in this study, the lowering
of the FPG threshold level in diagnosing IFG
Table 3. Comparison of Clinical Characteristics Among Subjects at Baseline Between the Old IFG Group and the
Newly Included IFG Group
Newly included IFG group Old IFG group p value
Subjects (n) 1335 494
Age (yrs) 40.9 ± 9.0 43.2 ± 8.8 < 0.001
Female (%) 7.3 4.7 0.04
Weight (kg) 69.4 ± 9.9 70.3 ± 10.4 0.10
BMI (kg/m
2) 24.2 ± 2.8 24.7 ± 3.0 0.002
Glucose (mmol/L) 5.75 ± 0.15 6.39 ± 0.24 < 0.001
Total cholesterol (mmol/L) 5.02 ± 0.89 5.13 ± 0.89 0.02
Systolic BP (mmHg) 128.1 ± 14.4 132.3 ± 16.5 < 0.001
Diastolic BP (mmHg) 80.1 ± 11.0 83.0 ± 12.3 < 0.001
Frequency of exercise (/wk) 1.40 ± 1.68 1.45 ± 1.64 0.51
Family history of diabetes (%) 9.3 7.6 0.25
BMI, body mass index; BP, blood pressure.
Data are expressed as means ± SD.
Old IFG was defined as a fasting plasma glucose value of 6.1 - 7.0 mmol/L (110 - 125 mg/dL) in the absence of previous diagnosis
of diabetes. Newly included diabetes was as a fasting plasma glucose value of 5.6 - 6.0 mmol/L (100 - 109 mg/dL) in the absence
of previous diagnosis of diabetes.So Hun Kim, et al.
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seems to be needed to properly identify subjects
who have risk of developing diabetes in Koreans.
A previous study on Korean subjects in a rural
area showed that the mean baseline FPG of
subjects who developed incident diabetes after 6
years follow up was 5.4 - 5.6 mmol/L.
21 The mean
FPG of subjects developing incident diabetes was
lower than that seen in our study which was 6.0
mmol/L. The difference in the FPG levels in those
who develop diabetes in these 2 studies seems to
be mainly due to the different follow up period.
The result of this study is similar to that seen
in other populations. The FPG value at the point
on the ROC curve closest to the ideal 100%
sensitivity and 100% specificity over the glycemic
range of 4.5 - 7.0 mmol/L to predict diabetes was
5.7 mmol/L in a Dutch population, 5.6 mmol/L in
a Pima Indian population, 5.4 mmol/L in a
Mauritius population, and 5.2 mmol/L in a San
Antonio population.
3,4,22,23 These values suggest
that 6.1 mmol/L was inappropriately high as a
lower limit for IFG. Thus, changing the IFG cut
point to 5.6 mmol/L would optimize its sensi-
tivity and specificity for predicting future
diabetes.
3 Further studies on the total benefit or
cost to an individual who is diagnosed with IFG
by the new criterion, compared to the old IFG
criterion, are needed to evaluate the effect of the
change of the diagnostic criteria on our health
system. Based on the NHANES III data, about
89% of 25- to 75-yr-olds with an FPG of 100 - 109
mg/dL have another indication (high BMI, hyper-
tension, or dyslipidemia) for diet and exercise,
and therefore, could be identified and treated
without being labeled as having IFG. Thus, of all
patients newly labeled as “IFG”, only 11% have
no other indication for diet and exercise recom-
mendations.
7 Since little is known about the
socioeconomic benefit of lowering the IFG cutoff
point, these outcomes should be evaluated to be
truly sure that the new IFG criteria will be
beneficial.
There are several limitations in the present
study. First, the diagnosis of diabetes was based
on a single measurement of FPG. Although the
oral glucose tolerance test (OGTT) is recognized
as a valid way to diagnose diabetes, use of the test
for diagnostic purposes in clinical practice has
been discouraged for several reasons (e.g., incon-
venience, less reproducibility, great cost). The
measurement of FPG is less expensive and less
intrusive than the 2-h PG. Commonly, in clinical
practice, risk prediction will occur using only the
fasting level without knowledge of the 2-h value.
The ADA expert committee encourages the use of
fasting glucose rather than the OGTT for the
diagnosis of diabetes and other categories of
glucose regulation in clinical and epidemiological
studies.
1 Second, since no OGTTs were conducted,
the prevalence of diabetes could have been under-
estimated. In a study of elderly Koreans, the
prevalence of newly diagnosed diabetes was
found to be higher according to the World Health
Organization (WHO) criteria using OGTTs than
by the ADA criteria using fasting glucose alone.
24
In conclusion, the lowering of the IFG criteria
from 6.1 mmol/L (110 mg/dL) to 5.6 mmol/L (100
mg/dL) increased the prevalence of IFG from
6.6% to 24.4%. The optimal cutoff for the baseline
FPG that predicts incident diabetes after 2 years
was 5.7 mmol/L (103 mg/dL). The lowering of
the IFG threshold to 5.6 mmol/L should have
benefit over the old threshold (6.1 mmol/L) since
it could optimize sensitivity and specificity for
predicting the future onset of diabetes in the
Korean population.
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